The HYPROTIN project addressed a significant gap in our understanding of tumorigenesis caused by mutations in the BRCA1 gene, particularly related to hereditary breast and ovarian cancer (HBOC). BRCA1 is an intrinsically disordered protein (IDP) that regulates critical cellular processes such as DNA replication. Mutations in BRCA1 disrupt these processes, leading to uncontrolled tissue growth and cancer. The lack of detailed knowledge about the molecular mechanisms of BRCA1’s interactions with other proteins and DNA—its "dark interactome"—limits the development of effective, targeted treatments. Current experimental techniques, such as conventional nuclear magnetic resonance (NMR), are unable to study these weak and transient interactions at the necessary temporal and spatial resolution under physiological conditions.
Breast cancer is one of the most prevalent cancers worldwide, affecting 12% of all women and 0.1% of all men during their lifetimes. For individuals with BRCA1 mutations, the risk increases to as much as 55-65%. Despite the immense social and economic burden of breast and ovarian cancer, mastectomy remains the most common preventive measure due to the absence of precise, targeted therapeutic options. This highlights an urgent need to improve our understanding of the underlying molecular biology to develop more effective, non-invasive treatments. Advancing knowledge of BRCA1 interactions could lead to breakthroughs in drug discovery and early-stage cancer detection, improving patient outcomes and reducing healthcare costs.
The HYPROTIN project had three primary objectives:
1. Methodological Innovation:
- Develop advanced tools for hyperpolarized nuclear magnetic resonance (NMR) to enable atomic-level resolution of BRCA1’s interactions under physiological conditions.
- Establish time-resolved monitoring techniques to study the kinetics of BRCA1’s interactions with other molecules in real-time.
2. Scientific Discovery:
- Decipher the "dark interactome" of BRCA1, focusing on its regulatory network, including interactions with transcription factors (e.g. MYC, MAX) and DNA binding sites (e.g. EBOX).
- Identify the structural and kinetic mechanisms driving these interactions to understand their role in tumorigenesis.
3. Application and Impact:
- Use insights from the interactome to facilitate the development of targeted therapeutic strategies that restore healthy cell cycle regulation in HBOC patients.
- Build a platform for broader applications of hyperpolarized NMR to study other intrinsically disordered proteins, which are implicated in various diseases beyond cancer.
